As the first company in the world to offer fat derived stem cell services for veterinary use, Vet-Stem has rapidly developed the market, providing treatments to over 10,000 horses, dogs, cat and exotic species.
Poway, California (PRWEB) May 08, 2014
Vet-Stem, Inc., announced that a major patent has been issued directly to Vet-Stem for New Zealand. This patent covers methods for extracting/preparing and using adipose tissue-derived stem cells for preventing or treating diseases in any mammal, including humans. This patent will provide coverage for the ongoing commercial and development programs at Vet-Stem and for its licensees in Australasia. This patent may be available for licensing for human applications to other companies interested in working in this field.
Of particular interest is the application to the rapidly evolving field of Regenerative Sports Medicine. This patent covers the preparation methods and use of adipose-derived stem cells in treating any type of disease, but specifically covers the use in injuries or diseases of the musculoskeletal system such as tendon tears, ligament injury and osteoarthritis.
This new patent issued to Vet-Stem adds to the many other patents in the Vet-Stem portfolio that cover methods of preparing and using regenerative cells from adipose. Vet-Stem has already had a similar patent issue in the EU and applications are pending in the US and other countries. In addition to these owned patents, Vet-Stem has exclusive worldwide rights to a portfolio of patents (over 50 issued and 70 pending patents) from Artecel, Inc. (including University of Pittsburgh patents) and the University of California, which further strengthens the company’s intellectual property position in this rapidly developing field.
As the first company in the world to offer fat derived stem cell services for veterinary use, Vet-Stem has rapidly developed the market, providing treatments to over 10,000 horses, dogs, cat and exotic species. “Intellectual property rights can be confusing in a rapidly developing market with evolving technology,” said Bob Harman, DVM, MPVM, CEO of Vet-Stem. “We needed to do everything possible to protect the market that we are creating in regenerative veterinary medicine and to ensure that the value of the company is optimized. The value of this technology has increased greatly since the founding of the company in 2002 as the business model, therapeutic activity of the cells, and ease of tissue collection have all been demonstrated.”
About Vet-Stem, Inc.
Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.’s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.